Sanofi ADR
American Depositary Receipt · NASDAQ
Live TMS charts are coming soon.
Paper trading. Simulated, no real money.
No public theses on SNY yet. When TMS traders open paper trades on it and make their thesis public, the long and short split, average conviction and hit rate show here.
Key stats load once market data is connected.
An analyst estimates Insmed could be worth $170 to $210 a share in a takeover, with Sanofi named in the feed. The item is an analyst view, not a confirmed deal or offer.
Unverified rumor. Not financial advice.
Insmed shares rose after a report that Sanofi may be interested in acquiring the company. The headline alone gives no details, and neither company has confirmed any takeover talks.
Unverified rumor. Not financial advice.
Jacobs has reportedly been selected by Sanofi for work on an insulin manufacturing facility in Frankfurt. The headline gives no contract value or scope details.
No SEC financials for SNY yet. Companies that file 10-K and 10-Q reports show revenue, earnings, cash flow and the balance sheet here.
Source: SEC filings (10-K, 10-Q).
Paper trading only. Nothing here is financial advice.